| Code | 0167F | ||||||||||
| MA number | EU/1/22/1673/002 | ||||||||||
| Product Form: | sol inj 1x0,165 ml/1,65 mg (striek.inj.napl.COP) | ||||||||||
| MA Status: | E - Valid centralised marketing authorisation | ||||||||||
| Type of procedure: | EU | ||||||||||
| MAH, country: | Midas Pharma GmbH, Germany | ||||||||||
| Therapeutic Class: | 64 - OPHTHALMOLOGICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 12 | ||||||||||
| Route of admin.: | Intravitreal use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(4) similar biological application |
| MA issued: | 25.08.2022 |
| Validity: | 25.08.2027 |
| SmPC + PL: |
European Medicines Agency's database
|
| Dokument: |
Ranibizumab_Prirucka pre pacientov.pdf
|
| Safety feature | Yes |
| Data update: | 03.06.2025 |
